Gait and upper-limb movement monitoring for healthy volunteers
Official title: Gait Analysis Parameter and Upper Limb Evaluation in Control Participants
Run by Centre Hospitalier Universitaire de Liege · NCT07136506 · Data updated 2026-11-12
This project will test a wrist-and-ankle wearable called Syde® to track walking and arm movements in healthy volunteers of all ages over two years.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liège) |
| Status | Recruiting |
| Started | September 24, 2025 |
| Main results expected | September 2028 |
| Study ends | December 2028 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT07136506 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy males or females of any age who can walk at least 10 meters unaided, have a BMI between 17 and 30, can comply with remote procedures, and have reliable internet access or the ability to upload device data onsite.
✕Probably not a fit
People with conditions affecting gait or recent limb surgery/trauma, pregnant women, elite national-level athletes, or those without reliable internet access are unlikely to be eligible or to benefit from this normative dataset.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This monocentric, fully remote study will enroll 200 healthy volunteers across the lifespan and collect continuous wrist-and-ankle movement data using the Syde® device. Participants will wear the device for 3-week periods every six months and complete all consent and follow-up visits remotely by phone or video. The primary aims are to build a normative longitudinal database of gait and upper-limb metrics and to measure device adherence and acceptability. Secondary aims include evaluating the reliability of digital endpoints and how demographic and lifestyle factors influence these measures.
Why it matters
Potential benefit: If successful, this work will produce age- and demographic-specific reference values for wearable-derived movement measures that can improve interpretation of digital endpoints and help design better neurological and rare-disease trials.
How similar studies have gone: Wearable measures from Syde® and ActiMyo® have been used successfully in DMD, SMA, and other populations and the SV95C metric has EMA endorsement, but assembling a full lifespan normative dataset is a novel extension.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female of different age groups * Signed informed consent form by participant him/herself or, in case of patients \<18 years old, signed informed consent form by patient's parents or legal guardians * Able to ambulate (minimum 10 meters without help) * Participant willing and able to comply with all study procedures Exclusion Criteria: * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs * Elite athletes (at the national level) * Pregnant women * A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion * An orthopedic, neuromuscular, or neurological pathology that affects the quality of the participant's walking gait * No access to unlimited internet connection or alternatively no capacity to come on-site to upload Syde data
Where it's running
-
Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
Liège, Belgium Recruiting
Study contacts
- Principal investigator: Laurent Servais, MD — Centre Hospitalier Universitaire de Liege
- Study coordinator: Nicolas Bovy
- Email: Nicolas.Bovy@citadelle.be
- Phone: +3243218095
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How age affects germinal center responses after flu and rabies vaccines
Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).
-
Magnetic field maps with NV sensors for non-invasive heart measurements
This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.
-
Methylation analyses using home-based self-sampling in women with and without gynecological disease
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.
-
Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products
This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.
-
A safe, carefully dosed test of TBD11 in healthy adults
This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.
-
Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm
This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.